Hong Kong Virus Panel Agrees to Lower Vaccination Age to 12
(Bloomberg) -- Hong Kong's expert advisory panel on Covid vaccinations has agreed to expand eligibility to children as young as 12, according to a person familiar with the matter, as the city works to boost lackluster inoculation rates.
The younger group will be eligible to receive BioNTech SE vaccines, said the person, who asked not to be identified discussing internal plans. Still, the move is subject to final approval by the government, the person added. The recommendation was earlier reported by Cable TV.
Hong Kong's government said it has received an application about lowering of the age limit for BioNTech vaccines to people as young as 12 and the relevant phase-three clinical trial data from Fosun Pharma, the distributor of BioNTech vaccine in Greater China, according to a statement on Tuesday.
“The Secretary for Food and Health will consider the suggestions by the advisory panel,” it said. “It is expected that a decision on the application for lowering the age limit for vaccination can be reached in short time.”
The government has routinely followed the panel's vaccine recommendations, usually within days.
That move follows approvals from the U.S. and Canada, paving the way for the mass vaccination of students before the start of the next school year. Singapore also authorized vaccines from Pfizer Inc. and BioNTech SE for children as young as 12 years old earlier in May.
Hong Kong Chief Executive Carrie Lam announced a campaign on Monday to accelerate the city's slow inoculation rates by September, with measures such as paid leave for vaccinated civil servants and possible additional restrictions for unvaccinated citizens. The Hong Kong Monetary Authority urged all financial institutions to “strongly encourage” staff in client-facing roles or support functions to get vaccinated.
Read more: Hong Kong Eases Quarantine for Vaccinated Execs, Drawing Ire
Hong Kong is increasingly looking to enlist businesses in the vaccination rollout, which has been impeded by a lack of trust in the Beijing-backed government and concerns about rare side-effects. The government has been ramping up efforts to encourage citizens to receive vaccines by providing policy incentives like reopening bars and shortening the quarantine period for vaccinated people.
Read more: Hong Kong Turns to Businesses to Fix Foundering Vaccine Push
In April, the government opened up vaccines to residents aged 16 and older. People 16 and above are allowed to receive BioNTech vaccines, while those older than 18 can opt for shots made by China's Sinovac Biotech Ltd. Those under 18 need parental consent to be vaccinated.
©2021 Bloomberg L.P.
-
One El Nino, India Can Handle. Two Could Break The Granary
India's grain stocks can absorb one bad year, but a second El Nino could drain the buffer in two to three years, economists say.
-
India's Troika Of Good Luck | Joining The Dots
As Jensen Huang's exit drags Nvidia down, a cooling AI trade and resilient earnings have revived investor interest in India. A likely RBI rate hike looms.
-
Talking Points This Week: Leadership Shock At Nvidia, Earnings Strength, And The Fog Over Hormuz
The Anthropic IPO pricing and first trading day, Nvidia's upcoming earnings, and any fresh signals from Iran will set the tone for the following week.
-
Signature Play: The Classic Cocktail Is Dead. Or Is It?
Classic cocktails are disappearing from India's cocktail menus. But they're still being ordered, taught to bartenders and borrowed from. So, who's really having the last drink?
-
A New Samvat Wishlist: Inclusive Prosperity And Human Development
India has strengthened its economic foundations through infrastructure, digital access and enterprise. Its next growth chapter must deepen productivity, create better livelihoods and widen participation in prosperity.
-
Love, Sex Aur Dhokha: The Audacious Plot To Spy On Jensen Huang
A Taipei dinner, a Singapore chip buyer and a suspected Chinese asset: inside the alleged spy operation that got close to NVIDIA's Jensen Huang.
-
Ten Things I Learnt This Samvat
Patience can be a trap. Cheap stocks can stay cheap. Leverage can wipe you out. What did Samvat 2082 teach us? Niraj Shah writes on 10 lessons from the year gone by.
-
Talking Points This Week: Tech Nerves, FII Buying, And A Faraway Banking Shock
The global markets are not shining this Diwali. The exception in the large markets is, India.
-
Midterm Rally Lasted A Day. The Hard Reality Of A Divided US May Last Two Years | Opinion
Between a contested AI boom, a debt ceiling that arrives in 2027 and a president with every incentive to act alone, the next two years may prove more volatile than the first day's rally suggests.
-
Blue Wave Will Derail the AI Trade but Won't Dismantle the AI Era | Unhedged Position
The Democrats' sweep of the US Congress will see politics collide with economic forces both over the long and short term.